B-Raf mutation: A key player in molecular biology of cancer

Experimental and Molecular Pathology

Volumn 95, Issue 3, 2013, Pages 336-342

  Rahman, M A ^a   Salajegheh, A ^a   Smith, R A ^a   Lam, A K Y ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

B Raf; BRAF; Colorectal cancer; Melanoma; Mutation; Thyroid cancer

Indexed keywords

B RAF KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELANOCORTIN 1 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN MLH1; RAF PROTEIN; BRAF PROTEIN, HUMAN;

B RAF GENE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CPG ISLAND; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; MELANOMA; MISSENSE MUTATION; MLH1 GENE; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; GENETICS; MUTATION; NEOPLASM; PATHOLOGY;

HUMANS; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84887258189     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.10.005     Document Type: Review

References (140)

1. Abdel-Malek Z.A., et al. The melanocortin 1 receptor and the UV response of human melanocytes-a shift in paradigm. Photochem. Photobiol. 2008, 84:501-508.
2. Amiri K.I., Richmond A. Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev. 2005, 24:301-313.
3. Assoian R.K., Schwartz M.A. Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr. Opin. Genet. Dev. 2001, 11:48-53.
4. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
5. Barnier J.V., et al. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. J. Biol. Chem. 1995, 270:23381-23389.
6. Bash J., et al. c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. Mol. Cell. Biol. 1997, 17:6526-6536.
7. Benhattar J., et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 1993, 104:1044-1048.
8. Bhatt K.V., et al. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005, 24:3459-3471.
9. Bond M., et al. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 1998, 435:29-34.
10. Bonner T.I., et al. Structure and biological activity of human homologs of the raf/mil oncogene. Mol. Cell. Biol. 1985, 5:1400-1407.
11. Borghaei R.C., et al. NF-kappaB binds to a polymorphic repressor element in the MMP-3 promoter. Biochem. Biophys. Res. Commun. 2004, 316:182-188.
12. Boyle P., Langman J.S. ABC Of colorectal cancer: epidemiology. Br. Med. J. 2000, 321:805-808.
13. Busca R., Ballotti R. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Res. 2000, 13:60-69.
14. Cantwell-Dorris E.R., et al. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 2011, 10:385-394.
15. Caronia L.M., et al. Role of BRAF in thyroid oncogenesis. Clin. Cancer Res. 2011, 17:7511-7517.
16. Catling A.D., et al. A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function. Mol. Cell. Biol. 1995, 15:5214-5225.
17. Catz S.D., Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 2001, 20:7342-7351.
18. Chadee D.N., et al. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4463-4468.
19. Ciampi R., Nikiforov Y.E. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007, 148:936-941.
20. Cohen Y., et al. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 2003, 95:625-627.
21. Conner S.R., et al. Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J. Biol. Chem. 2003, 278:34548-34554.
22. Cox A.D., Der C.J. The dark side of Ras: regulation of apoptosis. Oncogene 2003, 22:8999-9006.
23. Curtin J.A., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005, 353:2135-2147.
24. Daniotti M., et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004, 23:5968-5977.
25. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
26. Deng G., et al. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999, 59:2029-2033.
27. Deng L., et al. 2-Acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J. Biol. Chem. 2001, 276:413-420.
28. Deveraux Q.L., et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
29. Dhomen N., Marais R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 2007, 17:31-39.
30. Dhomen N., Marais R. BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am. 2009, 23:529-545. ix.
31. d'Ischia M., et al. Peroxidase as an alternative to tyrosinase in the oxidative polymerization of 5,6-dihydroxyindoles to melanin(s). Biochim. Biophys. Acta 1991, 1073:423-430.
32. Dong S.M., et al. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod. Pathol. 2005, 18:170-178.
33. Dumaz N., et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006, 66:9483-9491.
34. Durante C., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 2007, 92:2840-2843.
35. Erhardt P., et al. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 1999, 19:5308-5315.
36. Fabian J.R., et al. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 1993, 13:7170-7179.
37. Fransen K., et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25:527-533.
38. Garnett M.J., Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6:313-319.
39. Garnett M.J., et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 2005, 20:963-969.
40. Gerstenblith M.R., et al. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum. Mutat. 2007, 28:495-505.
41. Gray-Schopfer V.C., et al. The role of B-RAF in melanoma. Cancer Metastasis Rev. 2005, 24:165-183.
42. Greten F.R., Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004, 206:193-199.
43. Gu L.Q., et al. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid 2009, 19:347-354.
44. Guan K.L., et al. Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem. 2000, 275:27354-27359.
45. Guttridge D.C., et al. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999, 19:5785-5799.
46. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
47. Hingorani S.R., et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003, 63:5198-5202.
48. Hinz M., et al. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 1999, 19:2690-2698.
49. Houben R., et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 2004, 3:6.
50. Howe A.K., et al. Anchorage-dependent ERK signaling-mechanisms and consequences. Curr. Opin. Genet. Dev. 2002, 12:30-35.
51. Huebner K., et al. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:3934-3938.
52. Hundahl S.A., et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998, 83:2638-2648.
53. Iademarco M.F., et al. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J. Biol. Chem. 1992, 267:16323-16329.
54. Ikawa S., et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol. Cell. Biol. 1988, 8:2651-2654.
55. Ikehara N., et al. BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int. J. Cancer 2005, 115:943-950.
56. Ikenoue T., et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 2003, 63:8132-8137.
57. Ikenoue T., et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res. 2004, 64:3428-3435.
58. Johnson L.N., et al. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 1998, 430:1-11.
59. Karasarides M., et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
60. Kashani-Sabet M., et al. NF-kappa B in the vascular progression of melanoma. J. Clin. Oncol. 2004, 22:617-623.
61. Keates S., et al. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology 1997, 113:1099-1109.
62. Kerkhoff E., Rapp U.R. High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res. 1998, 58:1636-1640.
63. Kikuchi H., et al. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res. 2009, 69:8499-8506.
64. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
65. Kuo M.T., et al. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 2002, 21:1945-1954.
66. Lam K.Y., et al. Cyclin D1 expression in oral squamous cell carcinomas: clinicopathological relevance and correlation with p53 expression. J. Oral Pathol. Med. 2000, 29:167-172.
67. Lam A.K., et al. Papillary carcinoma of thyroid: a 30-year clinicopathological review of the histological variants. Endocr Pathol 2005, 16:323-330.
68. Lam A.K., et al. Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity. Hum. Pathol. 2008, 39:1229-1233.
69. Landi M.T., et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006, 313:521-522.
70. Liu D., et al. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 2007, 13:1341-1349.
71. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
72. Marais R., et al. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995, 14:3136-3145.
73. Marais R., et al. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 1997, 272:4378-4383.
74. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80:179-185.
75. Mason C.S., et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 1999, 18:2137-2148.
76. Michaloglou C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
77. Micheau O., et al. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 2001, 21:5299-5305.
78. Minoo P., et al. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J. Pathol. 2007, 212:124-133.
79. Moelling K., et al. Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 1984, 312:558-561.
80. Morrison D.K., Cutler R.E. The complexity of Raf-1 regulation. Curr. Opin. Cell Biol. 1997, 9:174-179.
81. Morrison D.K., et al. Identification of the major phosphorylation sites of the Raf-1 kinase. J. Biol. Chem. 1993, 268:17309-17316.
82. Namba H., et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 2003, 88:4393-4397.
83. Nappi A.J., Vass E. Hydrogen peroxide generation associated with the oxidations of the eumelanin precursors 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. Melanoma Res. 1996, 6:341-349.
84. Naysmith L., et al. Quantitative measures of the effect of the melanocortin 1 receptor on human pigmentary status. J. Invest. Dermatol. 2004, 122:423-428.
85. Ng I.O., et al. Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer 1998, 83:851-857.
86. Nikiforova M.N., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003, 88:5399-5404.
87. Pacifico F., Leonardi A. Role of NF-kappaB in thyroid cancer. Mol. Cell. Endocrinol. 2010, 321:29-35.
88. Pakneshan S., et al. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013, 45:346-356.
89. Palona I., et al. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 2006, 147:5699-5707.
90. Park S.J., et al. Frequent CpG island methylation in serrated adenomas of the colorectum. Am. J. Pathol. 2003, 162:815-822.
91. Patton E.E., et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 2005, 15:249-254.
92. Pikarsky E., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
93. Porra V., et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 2005, 90:3028-3035.
94. Pruitt K., et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J. Biol. Chem. 2005, 280:23363-23370.
95. Rajagopalan H., et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
96. Rapp U.R., et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:4218-4222.
97. Rapp U.R., et al. Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim. Biophys. Acta 2004, 1644:149-158.
98. Ravi R., et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 2001, 3:409-416.
99. Riesco-Eizaguirre G., et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr. Relat. Cancer 2006, 13:257-269.
100. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 1997, 9:180-186.
101. Rofstad E.K., Halsor E.F. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 2000, 60:4932-4938.
102. Roskoski J.R. RAF protein-serine/threonine kinases: structure and regulation. Biochem. Biophys. Res. Commun. 2010, 399:313-317.
103. Rouzaud F., et al. MC1R and the response of melanocytes to ultraviolet radiation. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2005, 571:133-152.
104. Rushworth L.K., et al. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 2006, 26:2262-2272.
105. Salajegheh A., et al. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma. Hum Pathol. 2013, 44:2204-2212.
106. Salajegheh A., et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur. J. Surg. Oncol. 2011, 37:93-99.
107. Sewing A., et al. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 1997, 17:5588-5597.
108. Smith R.A., et al. Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant. Hum. Pathol. 2011, 42:500-506.
109. Storm S.M., et al. Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 1990, 5:345-351.
110. Sturm R.A., et al. The role of melanocortin-1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res. 2003, 16:266-272.
111. Tang K.T., Lee C.H. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J. Chin. Med. Assoc. 2010, 73:113-128.
112. Tateyama H., et al. Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the saw-toothed structure may be related to inhibition of apoptosis. Am. J. Surg. Pathol. 2002, 26:249-256.
113. Um J.H., et al. Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene 2001, 20:6048-6056.
114. Urano Y., et al. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J. Invest. Dermatol. 1995, 104:928-932.
115. Valverde P., et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum. Mol. Genet. 1996, 5:1663-1666.
116. van de Stolpe A., et al. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J. Biol. Chem. 1994, 269:6185-6192.
117. Velho S., et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255.
118. Wan P.T., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
119. Wang C.Y., et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
120. Wang C.Y., et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 1999, 5:412-417.
121. Weber C.K., et al. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 2001, 61:3595-3598.
122. Weisenberger D.J., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 2006, 38:787-793.
123. Wellbrock C., Karasarides M. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 2004, 5:875-885.
124. Whelan J., et al. An NF kappa B-like factor is essential but not sufficient for cytokine induction of endothelial leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Nucleic Acids Res. 1991, 19:2645-2653.
125. Wittinghofer A., Nassar N. How Ras-related proteins talk to their effectors. Trends Biochem. Sci. 1996, 21:488-491.
126. Woods D., et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 1997, 17:5598-5611.
127. Xing M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 2005, 12:245-262.
128. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 2007, 28:742-762.
129. Xing M., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2005, 90:6373-6379.
130. Xing M., et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013, 309:1493-1501.
131. Yang S., et al. BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 2004, 28:1452-1459.
132. Yao B., et al. Phosphorylation of Raf by ceramide-activated protein kinase. Nature 1995, 378:307-310.
133. Yu X.M., et al. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery 2008, 144:934-940. (discussion 940-931).
134. Yu X.M., et al. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann. Surg. 2008, 247:483-489.
135. Yuen A.P., et al. Clinicopathologic significance of bcl-2 expression in the surgical treatment of oral tongue carcinoma. Eur. J. Surg. Oncol. 2002, 28:667-672.
136. Yuen S.T., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002, 62:6451-6455.
137. Zebisch A., Troppmair J. Back to the roots: the remarkable RAF oncogene story. Cell. Mol. Life Sci. 2006, 63:1314-1330.
138. Zhang B.H., Guan K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 2000, 19:5429-5439.
139. Zhou G., Kuo M.T. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem. 1997, 272:15174-15183.
140. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744.